321 related articles for article (PubMed ID: 36253823)
21. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
22. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
23. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
24. Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.
Wang P; Joberty G; Buist A; Vanoosthuyse A; Stancu IC; Vasconcelos B; Pierrot N; Faelth-Savitski M; Kienlen-Campard P; Octave JN; Bantscheff M; Drewes G; Moechars D; Dewachter I
Acta Neuropathol; 2017 May; 133(5):731-749. PubMed ID: 28083634
[TBL] [Abstract][Full Text] [Related]
25. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
26. The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.
Buchholz S; Zempel H
Alzheimers Dement; 2024 May; 20(5):3606-3628. PubMed ID: 38556838
[TBL] [Abstract][Full Text] [Related]
27. Nitration of tau protein is linked to neurodegeneration in tauopathies.
Horiguchi T; Uryu K; Giasson BI; Ischiropoulos H; LightFoot R; Bellmann C; Richter-Landsberg C; Lee VM; Trojanowski JQ
Am J Pathol; 2003 Sep; 163(3):1021-31. PubMed ID: 12937143
[TBL] [Abstract][Full Text] [Related]
28. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
29. Minimalistic in vitro systems for investigating tau pathology.
Hallinan GI; Pitera AP; Patel P; West J; Deinhardt K
J Neurosci Methods; 2019 May; 319():69-76. PubMed ID: 30278185
[TBL] [Abstract][Full Text] [Related]
30. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
[TBL] [Abstract][Full Text] [Related]
31. Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells.
Arnaud LT; Myeku N; Figueiredo-Pereira ME
J Neurochem; 2009 Jul; 110(1):328-42. PubMed ID: 19457109
[TBL] [Abstract][Full Text] [Related]
32. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
[TBL] [Abstract][Full Text] [Related]
33. In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model.
Marinković P; Blumenstock S; Goltstein PM; Korzhova V; Peters F; Knebl A; Herms J
Brain; 2019 Apr; 142(4):1051-1062. PubMed ID: 30847469
[TBL] [Abstract][Full Text] [Related]
34. Use of Affinity Purification-Mass Spectrometry to Identify Phosphorylated Tau Interactors in Alzheimer's Disease.
Pires G; Ueberheide B; Wisniewski T; Drummond E
Methods Mol Biol; 2023; 2561():263-277. PubMed ID: 36399275
[TBL] [Abstract][Full Text] [Related]
35. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
36. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies.
Yoshida M
Neuropathology; 2006 Oct; 26(5):457-70. PubMed ID: 17080726
[TBL] [Abstract][Full Text] [Related]
37. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
[TBL] [Abstract][Full Text] [Related]
38. Targeting tauopathy with engineered tau-degrading intrabodies.
Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
[TBL] [Abstract][Full Text] [Related]
39. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
Ferreira A; Bigio EH
Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
[TBL] [Abstract][Full Text] [Related]
40. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
